No significant enhancement of protection by Tat-expressing Sendal viral vector-booster in a macaque AIDS model

AIDS

Volumn 17, Issue 9, 2003, Pages 1392-1394

  Matano, Tetsuro ^a,b   Kano, Munehide ^b   Takeda, Akiko ^a,b   Nakamura, Hiromi ^b   Nomura, Nobuhiko ^c   Furuta, Yousuke ^c   Shioda, Tatsuo ^d   Nagai, Yoshiyuki ^b,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c TOYAMA CHEMICAL CO LTD   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e TOYAMA INSTITUTE OF HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAG PROTEIN; GAMMA INTERFERON; TRANSACTIVATOR PROTEIN; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MACACA; NONHUMAN; PRIORITY JOURNAL; SENDAI VIRUS; VACCINATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; GENES, TAT; IMMUNIZATION, SECONDARY; MACACA MULATTA; MODELS, ANIMAL; SENDAI VIRUS; TREATMENT FAILURE; VACCINES, DNA;

EID: 0038336955     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200306130-00015     Document Type: Article

References (11)

1. McMichael A, Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat Rev Immunol 2002, 2:283-291.
2. Matano T, Kano M, Odawara T, Nakamura H, Takeda A, Mori K, et al. Induction of protective immunity against pathogenic simian immunodeficiency virus by a foreign receptor-dependent replication of an engineered avirulent virus. Vaccine 2000, 18:3310-3318.
3. Kato A, Kiyotani K, Sakai Y, Yoshida T, Nagai Y. The paramyxovirus, Sendal virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J 1997, 16:578-587.
4. Kano M, Matano T, Kato T, Nakamura H, Takeda A, Suzaki Y, et al. Primary replication of a recombinant Sendal viral vector in macaques. J Gen Virol 2002, 83:1377-1386.
5. Matano T, Kano M, Nakamura H, Takeda A, Nagai Y. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA-prime/Sendai viral vector-boost regimen. J Virol 2001, 75:11891-11896.
6. Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemaemia. Nature 2000, 407:386-390.
7. Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, Baroncelli S, et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999, 5:643-650.
8. Pauza CD, Trivedi P, Wallace M, Ruckwardt TJ, Le Buanec H, Lu W, et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci USA 2000, 97:3515-3519.
9. Stittelaar KJ, Gruters RA, Schutten M, van Baalen CA, van Amerongen G, Cranage M, et al. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 2002, 20:2921-2927.
10. Allen TM, Mortara L, Mothe BR, Liebl M, Jing P, Calore B, et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 2002, 76:4108-4112.
11. Lu Y, Pauza CD, Lu X, Montefiori DC, Miller CJ. Rhesus macaques that become systemically infected with pathogenic SHIV B9.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:6-18.